Your browser doesn't support javascript.
loading
In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.
Annunziato, Stefano; Lutz, Catrin; Henneman, Linda; Bhin, Jinhyuk; Wong, Kim; Siteur, Bjørn; van Gerwen, Bas; de Korte-Grimmerink, Renske; Zafra, Maria Paz; Schatoff, Emma M; Drenth, Anne Paulien; van der Burg, Eline; Eijkman, Timo; Mukherjee, Siddhartha; Boroviak, Katharina; Wessels, Lodewyk Fa; van de Ven, Marieke; Huijbers, Ivo J; Adams, David J; Dow, Lukas E; Jonkers, Jos.
Affiliation
  • Annunziato S; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lutz C; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Henneman L; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bhin J; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wong K; Transgenic Core Facility, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Siteur B; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Gerwen B; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Korte-Grimmerink R; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Zafra MP; Wellcome Trust Sanger Institute, Cambridge, UK.
  • Schatoff EM; Preclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Drenth AP; Preclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Burg E; Preclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Eijkman T; Division of Hematology and Medical Oncology, Department of Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • Mukherjee S; Division of Hematology and Medical Oncology, Department of Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • Boroviak K; Weill Cornell/Rockefeller/Sloan Kettering Tri-I MD-PhD Program, New York, NY, USA.
  • Wessels LF; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van de Ven M; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Huijbers IJ; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Adams DJ; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Dow LE; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Jonkers J; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
EMBO J ; 39(5): e102169, 2020 03 02.
Article in En | MEDLINE | ID: mdl-31930530
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / CRISPR-Cas Systems / Gene Editing Limits: Animals Language: En Journal: EMBO J Year: 2020 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / CRISPR-Cas Systems / Gene Editing Limits: Animals Language: En Journal: EMBO J Year: 2020 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom